Announcing the launch of Breakthroughs Today, Cures Tomorrow, our 20th anniversary campaign!
By Anna Greene, PhD, NETRF Director of Research What if small intestine neuroendocrine tumors (SI-NETs), often diagnosed in people over age 60, actually begin decades
By Anna Greene, PhD, NETRF Director of Research An important advancement in neuroendocrine neoplasm (NEN) patient care has been released: the Position Statement on Nutritional
The world’s first clinical trial for CAR T-cell therapy in neuroendocrine tumors has advanced to a higher dose level, an indication of progress. Advancing to
By Anna Greene, PhD, NETRF Director of Research For many patients newly diagnosed with small, nonfunctioning pancreatic neuroendocrine tumors (PanNETs), active surveillance (AS) with regular
By Anna Greene, PhD, NETRF Director of Research A recent study by Suriya Baskar, MD, and Udhayvir Singh Grewal, MD, published in the Journal of
Perspective Therapeutics has begun enrolling participants into the next phase of its clinical trial of a new targeted alpha radiation therapy for neuroendocrine tumors (NETs).
At the Neuroendocrine Tumor Research Foundation (NETRF), we believe that the path to better treatments and cures, starts with research. However, ensuring that we fund
By Anna Greene, PhD, NETRF Director of Research The landscape of biomedical research is undergoing a seismic shift. This year alone, the NIH has awarded
At NETRF, our annual Request for Applications (RFA) is a cornerstone of our mission to fund innovative research in neuroendocrine cancer. This two-stage process is
By Anna Greene, PhD, Director of Research, NETRF Pancreatic neuroendocrine tumors (PanNETs) are a rare but increasingly detected cancer, thanks in part to more widespread